PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Analysts In Media, Inc. (AIM, Inc.)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Analysts in Media Announces Release of Q3 Edition of Future Pharmaceuticals - Analysts In Media released the Q3 August 2006 edition of Future Pharmaceuticals a high-level publication both online and in print, designed to provide senior-level business and technology executives with an in-depth analysis
Analysts in Media Announces Release of Q3 Edition of Future Pharmaceuticals

 

NewswireToday - /newswire/ - New York City, NY, United States, 2006/08/23 - Analysts In Media released the Q3 August 2006 edition of Future Pharmaceuticals a high-level publication both online and in print, designed to provide senior-level business and technology executives with an in-depth analysis.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Analysts In Media, Inc. (AIM) released the Q3 August 2006 edition of Future Pharmaceuticals (FP) a high-level publication both online and in print, designed to provide senior-level business and technology executives with an in-depth analysis of, and key insight into market trends and innovative technologies within the Pharmaceutical and Biotechnology industry.

This Q3 edition of FP features keynote editorial thought leadership from the most respected industry analysts, experts, and solution providers within the Pharmaceutical and Biotechnology world. The leading topics of discussion in this edition include Drug Discovery, Clinical Trails, Sales and Marketing, Learning and Training, and Conferences and Meetings.

Featured editorial contributors include:

• Nancy Grey, Director of Pharmacovigilance Education and Process Documentation in the Safety and Risk Management Organization, Pfizer.
• Janice Arnold, Associate Director of Marketing and Sales Information Analysis, Daiichi Sankyo
• Rebecca Kush, President, Clinical Data Interchange Standards Consortium (CDISC)
• Daniel C. Sullivan, Associate Director, National Cancer Institute

Drug Discovery:
Dr. Daniel C. Sullivan, Associate Director, National Cancer Institute, Fred Vinick, Senior VP of Drug Discovery. Genzyme Corporation, and Samuel Aronson, Director of IT, Harvard Medical Center

Clinical Trials:
Rebecca Kush, President, CDISC, Kenneth Getz, Senior Research Fellow, Tufts Center for the Study of Drug Development, and Roni Thaler, President and CEO, CISCRP

Sales and Marketing: Janice Arnold, Associate Director of Marketing and Sales Information Analysis, Daiichi Sankyo

Learning and Training:
Nancy Grey, Director of Pharmacovigilance Education Documentation in the Safety and Risk Management Organization, Pfizer, Stephen McGuffin, Assistant VP Sales Training and Management Development, Wyeth, and Don Kraft Associate Director of Human Resources (Learning and Organizational Development Department), Genentech

“We are delighted that these thought leaders have been kind enough to lend their expertise to this edition of the Future Pharmaceuticals,” says Amir Nikaein, CEO. “This further cements our ambition to make FP the leading information resource for buyers of technology and services within the Pharmaceutical and Biotechnology industry.”

The publication is available in both print and online.

About Future Pharmaceuticals

Published by Analysts in Media, Inc., Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharmaceutical companies as well as small, specialty, and biotech, Future Pharmaceuticals is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide.

About Analysts In Media

Analysts In Media, Inc. is a leading global provider of specialized information services for the professional and enthusiast markets, actively bringing buyers and sellers together across targeted media channels – publications, events and online.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Analysts In Media, Inc. (AIM, Inc.)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Analysts in Media Announces Release of Q3 Edition of Future Pharmaceuticals

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alaina Cagliostro - AnalystsinMedia.com 
646-747-0560 acagliostro[.]analystsinmedia.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Analysts In Media, Inc. (AIM, Inc.) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Analysts In Media, Inc. (AIM, Inc.) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)